CEBPA and prostate adenocarcinoma: Differences in feature weights were more evident in cancer types with less marked iHet conservation, like androgen and mitogen-activated protein kinase (MAPK) pathways, as well as HNF1A and CEBPA TFs in kidney renal clear cell carcinoma (KIRC), liver hepatocellular carcinoma (LIHC), and prostate adenocarcinoma (PRAD).